Licorice
Licorice, licence 80000660: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Other names
- Reglisse
- Licence holder
- Holy Land Traditional Medications Inc.
- NPN or DIN-HM
- 80000660
- Status
- Active licence
- Licence date
- 5 August 2005
- Revision date
- 18 October 2024
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
- Conditions légales
Glycyrrhiza glabra L.: La portion journalière recommandée ne doit pas conduire à une ingestion d'acide glycyrrhizinique supérieure à 100 mg. L'étiquetage doit comporter un avertissement avec la teneur suivante: "Ne pas utiliser pendant plus de 6 semaines sans avis médical." L'étiquetage doit comporter un avertissement déconseillant l'emploi chez les enfants.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Glycyrrhiza glabra | 380.0 mg | Not calculated |
Non-medicinal ingredients
Eau, Maltodextrine, Stéarate de magnésium, Gélatine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2.0 Capsule | minimum: 3.0 Tous les jours ; maximum: 6.0 Tous les jours |
Uses authorised in Canada
Traditionally used in treating dry cough and other lung disorders, sore throat and laryngitis. Traditionally used in treating urinary and intestinal inflammation. Traditionally used in treating rheumatism and joint pain as an anti-inflammatory.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Consult a health care practitioner before taking if you have diabetes or hypokalemia. Consult a health care practitioner before taking if you are taking any kind of hormonal therapies, diuretics, potassium depleting agents, MAO inhibitors. Consult a health care practitioner if symptoms persist.
- Contre-indications
Do not use if you are pregnant or breastfeeding. Do not use if you have impaired kidney or liver functions, high blood pressure or heart disease. Do not use if you are a man with decreased libido. Keep out of reach of children.
Source
Official Health Canada record, licence 80000660
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2024. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.